With the development of technology, new medical treatment procedures are advancing and stem cells are becoming popular. Currently, websites in China are flooded with all kinds of information – stem cell treatment for Parkinson’s disease and examples of how amazing the efficacy of stem cell treatment has been for so-and-so Parkinson’s disease patients who have been significantly improved or cured by stem cell treatment. However, in my career as a doctor, I have met some patients with Parkinson’s disease who have undergone stem cell treatment, and the caliber of all patients is “ineffective”, and some patients even have the feeling that they are “duped”, and the efficacy does not seem to be so “miraculous”. The cost of treatment is quite high, several tens of thousands of dollars for one treatment. The so-called stem cell therapy is nothing more than the input of stem cells through blood or the surgical implantation of stem cells into the brain in order to have a miraculous effect. A Chinese cnki search for “Parkinson’s disease” and “stem cells” yielded 11,351 results, indicating that there are indeed many articles on stem cells and Parkinson’s disease, but once clinical or progress is involved, the conclusion is ” There is no clear evidence that “stem cells” are clinically effective in treating “Parkinson’s disease”. There are very few international articles (www.pubmed.com) on stem cells for clinical treatment of Parkinson’s disease, and the search terms include stem cells and Parkinson’s disease, and only three studies are included in clinical studies and human studies, one from China, one from India, and one from an unknown country, and published in very cold journals. Among the English-language articles related to this topic, there are articles on transplantation in prestigious neurology journals (Ann Neurol 1995 and Arch Neurol 1999), but not on “stem cell transplantation” but on “embryonic nigrostriatal transplantation”. “In addition, there are also case reports of embryonic midbrain tissue transplantation in leading journals (N Engl J Med 1995). For ethical reasons and uncertain efficacy, transplantation therapy (hepatocytes) is not routinely applied in the clinic and is still in the experimental stage. It is worth noting that in 2011 the Lancet Neurol published an article on transplantation for Parkinson’s disease in which human retinal pigment epithelial cells were implanted into the human brain with a 12-month follow-up and were found to be ineffective and a total of 9 patients (out of 71) died at the final follow-up, 1 case possibly related to surgery. Therefore, stem cell therapy for Parkinson’s disease is still in the experimental stage and it is too early to be widely used in the clinic. I hope that patients or their families should be calm when they search for stem cell therapy for Parkinson’s disease on the internet, because the only methods that have clear efficacy and are widely used in clinical practice are drugs and stereotactic deep brain electrical stimulation or destruction.